A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence
A Randomized, Subject and Evaluator Blinded, Sham Controlled, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx for the Treatment of Fecal Incontinence
Sponsor: Bausch Health Americas, Inc.
This NA trial investigates Fecal Incontinence and is currently completed. Bausch Health Americas, Inc. leads this study, which shows 11 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Oct 2022 — Dec 2022 [monthly]
Completed NA
▶ Show 6 earlier versions
-
Jan 2021 — Oct 2022 [monthly]
Completed NA
-
Sep 2020 — Jan 2021 [monthly]
Completed NA
-
Jan 2020 — Sep 2020 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jun 2018 — Jan 2020 [monthly]
Unknown Status NA
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
- Galderma R&D
- Oceana Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .